Is Body Mass Index a Prognostic Factor in Metastatic HER2-Positive Breast Cancer? A Real-World Multicenter Study.

ABSTRACT: Background and Objectives: The prognostic significance of body mass index (BMI) in metastatic HER2-positive breast cancer (BC) remains unclear, with previous studies yielding conflicting results. This multicenter real-world study aimed to investigate the prognostic role of BMI in this patient population. Materials and Methods: A total of 169 female patients with metastatic HER2-positive BC who received trastuzumab-based treatment between 2010 and 2024 were included. Patients were categorized by BMI (<30 kg/m² vs. ≥30 kg/m²). The primary endpoints were overall survival (OS) and progression-free survival (PFS). Kaplan-Meier and Cox regression analyses were performed overall and in subgroups stratified by hormone receptor (HR) status. Results: In the

SUBMITTER: Birsin Z 

PROVIDER: S-EPMC12471550 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature